PharVision Advisers
PTEN icon

PharVision Advisers’s Patterson-UTI PTEN Stock Holding History

PharVision Advisers’s Portfolio PTEN Stock Details PTEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-11,085
Closed -$102K – 64
2026
Q2 		$102K Buy
+11,085
New +$124K 1.92% 18
2026
Q1 		– Sell
-31,193
Closed -$191K – 520
2025
Q4 		$191K Buy
31,193
+367
+1% +$2.19K 0.1% 579
2025
Q3 		$160K Buy
+30,826
New +$177K 0.09% 558

Other funds holding PTEN

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
DePrince Race & Zollo Inc (DRZ)
DePrince Race & Zollo Inc (DRZ) Winter Park, Florida $5.66B AUM 23.19% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $61B AUM 26.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Penn Capital Management
Penn Capital Management Philadelphia, Pennsylvania $1.37B AUM 42.56% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return

PharVision Advisers's PTEN Position: Q3 2026 in Review

PharVision Advisers sold out of Patterson-UTI (PTEN) in Q3 2026, closing a stake of 11,085 shares — an estimated $102K sold.

PharVision Advisers first reported a position in PTEN in Q3 2025 and held it in 3 quarters. The position peaked at $191K in Q4 2025. 190 funds tracked by Wall St. Rank hold PTEN as of Q3 2026.

  • PharVision Advisers reported no remaining Patterson-UTI position as of Q3 2026 after selling out during the quarter.
  • PharVision Advisers sold 11,085 Patterson-UTI shares in Q3 2026, an estimated $102K.
  • PharVision Advisers first reported a position in Patterson-UTI in Q3 2025 and held it in 3 quarters.
  • PharVision Advisers's Patterson-UTI position peaked at $191K in Q4 2025.
  • 190 funds tracked by Wall St. Rank held Patterson-UTI as of Q3 2026.

Based on PharVision Advisers's 13F filing for Q3 2026, filed 29 Oct 2026.